Hyperphosphorylated Tau is a pathologic hallmark of the neurofibrillary tangles in Alzheimer’s disease (AD). Tau proteins in plasma, particularly p-Tau217, are correlated with amyloid pathology and are emerging as valuable biomarkers of AD. Detecting p-Tau217 in the blood necessitates an assay* with an increased level of sensitivity and precision.
Our highly sensitive, Research Use Only (RUO) p-Tau217 assay will make testing more accurate and accessible in clinical research laboratories around the world.
Plasma p-Tau217 levels have shown correlation with amyloid pathology, which has implications for identifying neurodegenerative diseases such as AD. Elevated levels of p-Tau217 can help distinguish AD from other forms of dementia.
Measuring p-Tau217 may help to further research into AD pathology and flag samples from those with early-stage AD pathology.
We are committed to research that advances neurodegenerative disease diagnostics to make them more accessible to people around the world. Leveraging our history of IVD development, we are empowering cutting-edge research with high-quality, innovative assays that deliver accurate and affordable testing solutions at scale. Learn more about our comprehensive solutions.
Plasma p-Tau217 levels have shown correlation with amyloid pathology, which has implications for identifying neurodegenerative diseases such as AD. Elevated levels of p-Tau217 can help distinguish AD from other forms of dementia.
Measuring p-Tau217 may help to further research into AD pathology and flag samples from those with early-stage AD pathology.
Subheading B Clinical research on plasma p-Tau217 focuses on its promise as a blood-based biomarker for identifying AD pathology and staging disease.
Researchers using our RUO p-Tau217 assay to quantify p-Tau 217 concentrations can proceed with confidence given studies showing no detectable cross reactivity to non-phosphorylated Tau and no significant detected interference with common medications such as Donepezil, Memantine, Aripirazole, Galantamine, and Rivastigamine in human K2EDTA plasma samples.*
The following results are derived from internal studies and are intended solely for informational purposes. These findings are not intended to serve as official specifications or guarantees of performance.
| Assay Characteristic | Access APOE ε4 (RUO) | |
| Assay format | Two-step sandwich | |
| Recommended sample type(s) | Plasma (K2-EDTA) | |
| Unit of measure | Relative Light Units (RLU) | |
| Open reagent pack stability | 2 to 10°C for 14 days | |
| Open QC vial stability | 2 to 10°C for 14 days | |
| Sample volume (uptake) | Access 2: 30 μL/ratio determination | DxI 9000: 20 μL/ratio determination |
| Time to first result (approximate) | Access 2: ~22 minutes | DxI 9000: ~15 minutes |
| Imprecision (%CV RLU Ratio)* | Access 2: ~7.9 - 13.4% | DxI 9000: ~6.4 - 10.4% |
Thank you for your request.
A Beckman Coulter representative will contact you shortly.
2025-14533
English
